Glioblastoma Classification Revision Should Improve Patient Care
Radiation oncology researchers have revised the system used by doctors since the 1990s to determine the prognosis of people with glioblastoma, which is the most devastating of malignant brain tumors. The outdated system was devised for glioblastoma and related brain tumors that were treated by radiation therapy only, and it relied on clinical signs and symptoms...

Personalized Treatment Advances: Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors
Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations...

Positive Survival Trend Seen In Phase I Study Of Temsirolimus, Capecitabine
A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients...

Lapatinib Combined With Cetuximab Overcomes Resistance In EGFR-Driven Tumors
Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of information is behind a novel clinical trial at Georgetown Lombardi Comprehensive Cancer Center that combines cetuximab and lapatinib...

Keeping Ahead In The Medical Device Sector
"Medical device industry executives often develop products that are deemed safe and effective by the FDA, but that do not sell as they are not reimbursable," says Donald DeLauder, Executive Director - Corporate Innovation, Bayer Radiology and Interventional. They must spend more time on developing their products, he adds...

Optimizing Process Management In Medical Device Manufacturing
Medical device manufacturing executives are currently challenged with getting products to market faster; however with increased FDA regulatory requirements and validations, they must ensure that the manufacturing processes are robust, says William J. Bergen, President & Chief Executive Officer, MicroGroup. Effective and timely communication at each stage of production is crucial, he adds...

2nd Annual Market & Patient Access In Latin America Conference, 14-15 August 2012, Brazil
Understanding and optimizing market access strategies to penetrate the exciting and diverse South & Central America This event will provide participants with both a broad overview and specific detail of the market access, pricing and reimbursement environments in key Latin American countries such as Brazil, Mexico, Argentina, Colombia, Venezuela, Chile, Panama and Costa Rica...

Late Phase Leaders Forum, 8-10 October 2012, Vienna, Austria
Generating real-world data through late phase clinical and observational studies to achieve clinical, pharmacovigilance and marketing objectives 3 EVENTS IN ONE: Late Phase Leaders Forum (2 days) Comparative Effectiveness Research Leaders Day (1 day) Late Phase Research for Medical Devices (1 day) Day 1&2: October 8th & 9th - Late Phase Leaders Forum This event...

World Drug Repositioning Congress 2012, 11-13 September, London, UK
Drug development strategies for indication expansion and lifecycle extension 11 - 13 September 2012, Jumeirah Carlton Tower, London, UK As the cost and time of drug development persistently increases, drug repositioning is becoming an increasingly important strategy for large pharma and small biotech alike to successfully innovate in a more cost-effective environment...

World Biosimilars Congress 2012, 11-13 September, London, UK
Strategies for navigating the regulatory, manufacturing, sales and marketing route to biosimilar market entry. 11 - 13 September 2012, Jumeirah Carlton Tower, London, UK Get competitive insight into global regulatory strategies, and find out how to successfully bring biosimilars to-market in developed and developing regions...

Advances And Challenges In The Advancement Of Novel Therapeutic Cancer Vaccines - 19-20 September 2012
There is a great deal of unmet need in the effective treatment of numerous types of cancer, as long-term survival rates are still rather poor for a number of cancers. There is a strong need for more effective therapies that will extend survival, with potential for new immunostimulatory therapies and other biologics to stabilize cancer and prevent metastasis...

Partnering Trends Of Biosimilars And Biobetters In Emerging Markets - 24-25 September 2012
Biosimilar development costs are high with some industry leaders claiming estimates of $100-150 million. Even after this substantial investment there is no guarantee of immediate return. With the FDA, America's regulatory body, struggling to agree on a suitable approval pathway for biosimilars to reach market in the U.S...

3rd Annual Pharmacovigilance 2012, 31st August, Mumbai, India
Why Should You Attend? 3rd Annual Pharmacovigilance 2012 - "Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management" Get more from the event, with a broader scope bringing the whole communications value chain to gather...

The New Pharmacovigilance Legislation Will Impact US And European Drug Manufacturers
The Pharmacovigilance Legislation Will Come into Effect in July As the European Medicines Agency's new PV (pharmacovigilance) Legislation implementation date of July 2012 approaches, US and European pharmaceutical and biotech companies need to ask themselves if they are ready for the changes that lie ahead, says Paul Beninger, MD, FACP, Vice President, Global Patient Safety, Genzyme...

Biomarkers World Europe 2012, 22-24 May, London
New directions in drug discovery and development Biomarkers World Europe has established itself as the premier European event for biomarker development and implementation from discovery through to personalized medicine. Create an optimum biomarker strategy and be able to move towards personalised therapeutics with the insight of the world's leading biomarker scientists...